

PATHOLOGY & MOLECULAR REPORT

Endometrial Cancer Comprehensive Assessment

PATIENT DEMOGRAPHICS

| | |
|--------------|------------------------|
| Patient ID: | EC-2024-0847 |
| Age: | 64 years |
| BMI: | 32.5 kg/m ² |
| ECOG Status: | 1 |
| Diabetes: | No |

PATHOLOGICAL FINDINGS

| | |
|----------------------|--------------|
| FIGO Stage: | IA |
| Histology: | Endometrioid |
| Grade: | G3 |
| Myometrial Invasion: | <50% |
| LVI Status: | Focal |
| Lymph Node Status: | Negative |

MOLECULAR PROFILING RESULTS

| | |
|--------------|------------|
| POLE Status: | Wild-type |
| MMR Status: | Proficient |
| MLH1: | Intact |
| PMS2: | Intact |
| MSH2: | Intact |

MSH6: Intact

p53 Status: Abnormal

L1CAM Status: Positive

CTNNB1 Status: Wild-type

HORMONE RECEPTOR STATUS

Estrogen Receptor (ER): 100%

Progesterone Receptor (PR): 100%

INTERPRETATION

Based on the molecular profiling results, this tumor demonstrates p53 abnormal status with overexpression pattern, consistent with the TCGA p53abn molecular subtype. The presence of L1CAM positivity further supports aggressive tumor biology. Despite favorable anatomical staging (Stage IA, <50% myometrial invasion), molecular features indicate high-risk disease requiring consideration of adjuvant therapy.

This report is for demonstration purposes only.
Generated for OncoRisk EC Clinical Decision Support System